CN115867550B - 三唑酮化合物 - Google Patents

三唑酮化合物 Download PDF

Info

Publication number
CN115867550B
CN115867550B CN202180038087.XA CN202180038087A CN115867550B CN 115867550 B CN115867550 B CN 115867550B CN 202180038087 A CN202180038087 A CN 202180038087A CN 115867550 B CN115867550 B CN 115867550B
Authority
CN
China
Prior art keywords
methyl
triazolo
pyrimidin
amino
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180038087.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115867550A (zh
Inventor
G·A·布朗
M·S·康格里夫
S·P·安德鲁斯
J·S·马森
F·德弗洛里安
N·A·斯温
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexla Pharmaceuticals Uk Ltd
Original Assignee
Nexla Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexla Pharmaceuticals Uk Ltd filed Critical Nexla Pharmaceuticals Uk Ltd
Publication of CN115867550A publication Critical patent/CN115867550A/zh
Application granted granted Critical
Publication of CN115867550B publication Critical patent/CN115867550B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180038087.XA 2020-03-26 2021-03-25 三唑酮化合物 Active CN115867550B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994954P 2020-03-26 2020-03-26
US62/994954 2020-03-26
PCT/EP2021/057808 WO2021191380A1 (en) 2020-03-26 2021-03-25 Triazolone compounds

Publications (2)

Publication Number Publication Date
CN115867550A CN115867550A (zh) 2023-03-28
CN115867550B true CN115867550B (zh) 2025-01-03

Family

ID=75302568

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038087.XA Active CN115867550B (zh) 2020-03-26 2021-03-25 三唑酮化合物

Country Status (8)

Country Link
US (1) US12552799B2 (https=)
EP (1) EP4126871B1 (https=)
JP (1) JP7709454B2 (https=)
KR (1) KR20230049580A (https=)
CN (1) CN115867550B (https=)
AU (1) AU2021241886A1 (https=)
CA (1) CA3177057A1 (https=)
WO (1) WO2021191380A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138734A1 (en) * 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
WO2009111449A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
AU2011306358B2 (en) 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
AU2018233367B2 (en) 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
PL3611174T3 (pl) * 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
EP3774813A4 (en) * 2018-04-08 2021-11-17 BeiGene, Ltd. PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
WO2020010197A1 (en) * 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138734A1 (en) * 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
WO2009111449A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
JP2023519363A (ja) 2023-05-10
JP7709454B2 (ja) 2025-07-16
KR20230049580A (ko) 2023-04-13
EP4126871B1 (en) 2024-05-08
US20230146796A1 (en) 2023-05-11
WO2021191380A1 (en) 2021-09-30
US12552799B2 (en) 2026-02-17
AU2021241886A1 (en) 2022-10-27
EP4126871A1 (en) 2023-02-08
CN115867550A (zh) 2023-03-28
CA3177057A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2019243289B2 (en) Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
CN112513029B (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
JP6159028B2 (ja) Ｓｙｋ阻害剤
CN117957226A (zh) 作为sos1抑制剂的杂环化合物及其用途
WO2010138589A1 (en) Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US20120309739A1 (en) Akt / pkb inhibitors
WO2009053715A1 (en) Thienopyrimidiene derivatives as pi3k inhibitors
WO2008152394A1 (en) Pharmaceutical compounds
WO2012107465A1 (en) Heterocyclic compounds as pi3 kinase inhibitors
CN115867282B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
CN115867550B (zh) 三唑酮化合物
CN116782903A (zh) 取代的吡啶酮化合物及应用
WO2021156439A1 (en) Triazole compounds as adenosine receptor antagonists
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
WO2021191376A1 (en) Triazolone compounds
CN115433211A (zh) 吡嗪并吡啶酮类蛋氨酸腺苷转移酶2a抑制剂
HK40088927B (en) Triazolone compounds
HK40088927A (en) Triazolone compounds
EA046747B1 (ru) Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2а/a2b
HK40049450B (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40049450A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EA049133B1 (ru) Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2а/a2b

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Britain

Address after: Cambridge County, England

Applicant after: Nexla Pharmaceuticals UK Ltd.

Address before: Cambridge County, England

Applicant before: Heptares Therapeutics Ltd.

Country or region before: Britain

GR01 Patent grant
GR01 Patent grant